STOCK TITAN

Broadwood boosts Insight Molecular Diagnostics (IMDX) stake with $3M share buy

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. saw a major shareholder deepen its stake through a new stock purchase agreement. Broadwood Partners, Broadwood Capital and Neal C. Bradsher reported beneficial ownership of 12,081,932 to 12,082,089 common shares, equal to 37.4% of the company’s stock based on 32,297,028 shares outstanding.

On February 10, 2026, Broadwood Partners agreed to acquire an additional 521,739 shares from the company in a registered direct offering at $5.75 per share, for a combined purchase price of $2,999,999. The investors state the shares are held for investment and may engage with management and other shareholders on ways to enhance long-term value.

Positive

  • None.

Negative

  • None.

Insights

Large shareholder lifts stake via $3M direct stock purchase.

Broadwood Partners, together with Broadwood Capital and Neal C. Bradsher, reports beneficial ownership of up to 12,082,089 Insight Molecular Diagnostics shares, or 37.4% of the common stock based on 32,297,028 shares outstanding.

They entered a securities purchase agreement on February 10, 2026 to buy 521,739 additional shares in a registered direct offering at $5.75 per share, totaling $2,999,999. The filing describes the position as held for investment purposes.

The group indicates ongoing dialogue with management, the board and other significant shareholders about alternatives to maximize shareholder value over time. Any future changes in ownership or governance initiatives would be reflected in subsequent company communications and regulatory filings.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Broadwood Partners, L.P.
Signature:/s/ Neal C. Bradsher
Name/Title:Neal C. Bradsher / President of Broadwood Capital Inc.*
Date:02/12/2026
Broadwood Capital, Inc.
Signature:/s/ Neal C. Bradsher
Name/Title:Neal C. Bradsher / President*
Date:02/12/2026
Neal C. Bradsher
Signature:/s/ NEAL C. BRADSHER
Name/Title:NEAL C. BRADSHER*
Date:02/12/2026
Comments accompanying signature:
* This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many Insight Molecular Diagnostics (IMDX) shares does Broadwood now report owning?

Broadwood Partners and Broadwood Capital each report beneficial ownership of 12,081,932 Insight Molecular Diagnostics shares. Neal C. Bradsher reports beneficial ownership of 12,082,089 shares, equal to 37.4% of the common stock, based on 32,297,028 shares outstanding as of the filing date.

What new stock purchase did Broadwood agree to with Insight Molecular Diagnostics (IMDX)?

Broadwood Partners agreed to buy 521,739 Insight Molecular Diagnostics common shares from the company. The purchase is under a securities purchase agreement in a registered direct offering at $5.75 per share, for a combined total purchase price of $2,999,999, paid from Broadwood’s working capital.

What percentage of Insight Molecular Diagnostics (IMDX) does Broadwood’s group control?

The reporting group states beneficial ownership of 37.4% of Insight Molecular Diagnostics’ common stock. This percentage is calculated using 32,297,028 shares outstanding, adjusted to include warrants beneficially owned by the group, as described in the Schedule 13D/A amendment filing.

Why did Broadwood file Amendment No. 13 to its Schedule 13D on IMDX?

Amendment No. 13 was filed to report Broadwood Partners’ entry into a new securities purchase agreement. That agreement covers the acquisition of 521,739 additional Insight Molecular Diagnostics shares in a registered direct offering, updating the group’s beneficial ownership and related disclosure.

How is the new Insight Molecular Diagnostics (IMDX) share purchase funded by Broadwood?

The filing states Broadwood Partners’ 12,081,932 beneficially owned shares were purchased using its working capital. No specific borrowing was used other than any working-capital-related borrowing in the ordinary course of business, consistent with the firm’s existing investment approach.

What is Broadwood’s stated intent for its Insight Molecular Diagnostics (IMDX) investment?

The reporting persons state they acquired the shares for investment purposes. They note they have been, and may continue to be, in contact with management, the board and other significant shareholders regarding alternatives to maximize shareholder value over time.
Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

IMDX Rankings

IMDX Latest News

IMDX Latest SEC Filings

IMDX Stock Data

159.95M
25.68M
22.45%
56.62%
0.88%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
NASHVILLE